skip to main content

    Updated Visitor Guidelines

 

MENU

 

Researchers discover new genetic anomalies in lung cancer

By analyzing the DNA and RNA of lung cancers, researchers at the University of Michigan Rogel Cancer Center found that patients whose tumors contained a large number of gene fusions had worse outcomes than patients with fewer gene fusions.

Tailor-made cancer treatments? New cell culture technique paves the way

In a development that could lead to a deeper understanding of cancer and better early-stage treatment of the disease, University of Michigan researchers have devised a reliable way to grow a certain type of cancer cells from patients outside the body for study.

Program Members

The University of Michigan Rogel Cancer Center is built on a foundation of comprehensive, integrated and interdisciplinary specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is coordinated and tailored to the individual patient.

Meet the Urologic Oncology Physicians

The University of Michigan Rogel Cancer Center is built on a foundation of comprehensive, integrated and interdisciplinary specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is coordinated and tailored to the individual patient.

New technology improves prostate cancer biopsies

Prostate cancer specialists at the University of Michigan Rogel Cancer Center are refining prostate cancer diagnosis to better identify those cancers that are more likely to grow quickly and spread to other parts of the body.

Hayes elected president of American Society of Clinical Oncology

Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Rogel Cancer Center, was elected president of the American Society of Clinical Oncology, the largest and one of the most influential oncology professional societies.

Quality and Safety

This information is no longer available.

If you have questions, please contact our Cancer AnswerLine at 800-865-1125.

Pages